# Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

> **NCT05874713** · PHASE2 · COMPLETED · sponsor: **Seqirus** · enrollment: 480 (actual)

## Conditions studied

- Influenza, Human
- Infections
- Respiratory Tract Infections
- Virus Diseases
- Infection Viral

## Interventions

- **BIOLOGICAL:** aH5N8c on Day 1
- **BIOLOGICAL:** aH5N6c on Day 1
- **BIOLOGICAL:** aH5N8c on Day 22
- **BIOLOGICAL:** aH5N6c on Day 22
- **BIOLOGICAL:** aH5N8c on Day 202

## Key facts

- **NCT ID:** NCT05874713
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-07
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874713, "Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05874713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*